More big wins for the AstraZeneca-Daiichi Sankyo collaboration
This month has seen two groundbreaking approvals for Enhertu, which is developed and marketed by AstraZeneca and Daiichi Sankyo.
By
North America
Latest in
North America
Q32 Bio and Horizon partner to develop autoimmune disease treatment
Q32 is entitled to get $55m as initial consideration and staged development funding during the option period.
Injectable opportunities for CMOs despite internal capacity of big pharma sponsors
An increasing number of companies are turning to outsourcing to meet market demand for huge numbers of injectables.
By
Partner content
The Canadian life sciences hub that may not be on your FDI radar (but should be)
Investment Monitor explores the vibrant and emerging life sciences scene in Hamilton, Ontario.
US FDA approves Daiichi Sankyo-AstraZeneca’s Enhertu for lung cancer
The latest approval was based on the findings from the Phase II DESTINY-Lung02 trial of Enhertu.
Ceapro and McMaster extend partnership to develop Covid-19 therapy
This assessment in experimental models of lung fibrosis will aid in progressing the technology into a Phase I clinical trial.
GentiBio and BMS partner to develop inflammatory bowel disease therapies
BMS will make development and commercial milestone payments of up to $1.9bn to GentiBio.
FDA grants Orphan Drug status to Aro Biotherapeutics’ Pompe disease therapy
The company plans to advance ABX1100 into clinical trials in the middle of next year.